Core Scientific: AMD's Expansion Potential Supports A Cautious Buy

Core Scientific (CORZ) carries a “cautious Buy” rating and a $20-per-share valuation, according to the Seeking Alpha analysis, with 1,120 megawatts (MW) under contract and AMD holding rights to another 1,925 MW.

The analyst ties that valuation to major contracts with CoreWeave and AMD. The contracted 1,120 MW could generate $1.6 billion in annual NOI (net operating income), according to the source. AMD's additional reservation creates the expansion case around that operating base.

For Core Scientific, the market stakes are direct: contracted capacity anchors the operating case, AMD's reservation defines potential scale, and the $4.4 billion financing requirement puts capital cost at the center of returns. The analysis treats 1,120 MW as contracted and the additional 1,925 MW as conditional. That distinction matters.

What do the CoreWeave and AMD contracts establish?

The analyst attributes the $20-per-share valuation to major agreements with CoreWeave and AMD. The 1,120 MW under contract sits behind the potential $1.6 billion in annual NOI. The source does not allocate those megawatts between the two counterparties or provide a contract schedule.

That missing allocation prevents a precise assessment of dependence on either customer. The analysis nevertheless names both relationships as central to the rating. The CoreWeave and AMD agreements provide the operating case; AMD's 1,925 MW reservation supplies the expansion case.

The source also omits contract duration, utilization assumptions and power pricing. Its disclosed arithmetic remains simple: 1,120 MW of contracted capacity, a possible $1.6 billion in annual NOI and a $20-per-share valuation. Those figures establish the thesis, not its full sensitivity.

The analyst's use of the word potentially means the $1.6 billion should not be treated as guaranteed. That estimate depends on successful operation of the contracted capacity. The source provides no detailed mechanism for converting that potential into realized NOI. It offers no probability, cost curve or timing schedule.

How much expansion is tied to AMD?

AMD has reserved rights to an additional 1,925 MW, according to the analyst. That capacity is separate from the 1,120 MW already under contract. If AMD exercises the reservation, Core Scientific can pursue a larger buildout, meaning an expansion of infrastructure capacity. If AMD does not exercise it, the reservation contributes no contracted expansion.

The upside and downside share one trigger. According to the source, exercise would support the expansion thesis cited in the analysis. Non-exercise would leave 1,925 MW outside the contracted base and preserve the analyst's key risk.

The source gives AMD no exercise date, price, probability or phased schedule. The reservation therefore remains conditional capacity rather than contracted demand. The analyst does not attach a dollar value to the additional 1,925 MW.

That omission narrows the expansion case. The $20 valuation rests on major contracts and existing NOI potential; the 1,925 MW adds an upside path the source cannot yet quantify. The number is large. The reservation remains conditional.

How will AMD's buildout be financed?

The AMD buildout faces $4.4 billion in commitments, according to the analyst. Core Scientific plans to fund it with project bonds, or debt securities tied to a specific project, and other debt. The source is explicit that the planned buildout does not rely on equity.

The $4.4 billion debt plan keeps new shares out of the stated funding plan. It also makes borrowing costs central to the return case. The analyst identifies expensive financing as a key risk because it could reduce project returns.

The analysis does not disclose interest rates, bond tenors, lender terms, equity contributions or a financing timetable. The $4.4 billion therefore establishes the scale of the funding requirement, not the certainty of its terms. Scale, not certainty.

For Core Scientific shareholders, that distinction is material. The $4.4 billion debt-led expansion limits the stated reliance on equity issuance, while high-cost capital can weaken project returns and the $20 valuation. Both effects fit the source's cautious framing.

What execution risks could undermine the rating?

The analyst identifies three principal risks: AMD may not exercise the reserved capacity, electricity infrastructure delays may disrupt the buildout, and high-cost financing may reduce returns. The risks cover commercial commitment, project timing and capital cost.

• Reserved-capacity risk. The additional 1,925 MW depends on AMD. According to the source, non-exercise would deny Core Scientific the expansion contemplated by the cautious Buy.
• Infrastructure timing. Delays in electricity infrastructure could push back the AMD buildout described in the analysis. The source does not assign a delay period or quantify the financial effect.
• Financing cost. The analyst says costly project-bond or debt funding could weigh on returns from the $4.4 billion in commitments. No rate or threshold appears in the source.

The risks affect different parts of the thesis: AMD's commitment, project timing and financing returns. The source does not link any of the three specifically to the existing 1,120 MW. It presents them as risks to the broader expansion and valuation case.

None of the risks carries a numerical estimate beyond the 1,925 MW reservation and $4.4 billion commitment. The analysis provides no delay scenario, financing rate or exercise probability. The $20 valuation therefore remains sensitive to outcomes the source cannot forecast.

What does the cautious Buy rating mean?

The analyst assigns Core Scientific a cautious Buy, according to the source. That verdict combines a contracted operating base with a conditional expansion opportunity and a large debt-funded buildout. The rating depends on all three working together.

The source does not provide a current share price, expected return, forecast horizon or detailed valuation method. Readers therefore cannot calculate the implied upside from the $20 figure alone. They can identify what supports it: CoreWeave, AMD, 1,120 MW, $1.6 billion and $4.4 billion.

The qualification also reflects the source's explicit risk list. Electricity-infrastructure delays threaten the buildout described in the analysis. Expensive financing can weaken expected project returns. An AMD non-exercise removes the additional 1,925 MW. Each break affects a different link in the valuation case.

The cautious label is therefore more descriptive than predictive. It identifies a supported operating base but leaves the scale and economics of expansion unsettled. That is the source's position, not company guidance.

Who is behind the analysis, and what disclosures accompany it?

The author states: “I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.” The author also says the article expresses their own opinions, that they wrote it themselves, and that they receive no compensation other than from Seeking Alpha.

The author further reports no business relationship with any company whose stock appears in the article. The disclosure therefore places the analysis outside the author's stated securities holdings and corporate relationships. It does not convert the rating into company guidance.

Seeking Alpha warns that past performance is no guarantee of future results. The platform says it gives no recommendation or advice on whether an investment is suitable for a particular investor and that the author's views may not reflect Seeking Alpha as a whole.

Seeking Alpha also says it is not a licensed securities dealer, broker, US investment adviser or investment bank. Its analysts are third-party authors who include professional investors and individual investors and may not hold licensing or certification from an institute or regulatory body, according to the disclosure.

What should investors watch next?

The next material evidence will be AMD's decision on the 1,925 MW reservation, delivery of electricity infrastructure and the project-bond or debt terms attached to $4.4 billion in commitments. The source identifies each as a principal risk to its cautious Buy.

Those tests map directly to the $20-per-share valuation. Exercise, timely infrastructure and affordable financing would support the expansion path around 1,120 MW of contracted capacity and its potential $1.6 billion in annual NOI. Failure on any front would weaken the case for the $20 valuation. The evidence remains conditional.